Macular Degeneration News and Research RSS Feed - Macular Degeneration News and Research

Macular degeneration is a disease associated with aging that gradually destroys sharp, central vision. Central vision is needed for seeing objects clearly and for common daily tasks such as reading and driving.
Alternative splicing: a new approach to drug development? An interview with Lucy Donaldson

Alternative splicing: a new approach to drug development? An interview with Lucy Donaldson

RNA is becoming an interesting drug target as it takes possible intervention back one step to the synthesis of a target protein, instead of trying to block or inhibit a process. [More]
Age-related macular degeneration: an interview with Cathy Yelf, Macular Society

Age-related macular degeneration: an interview with Cathy Yelf, Macular Society

Age-related macular degeneration is a condition of the macula, a tiny area of the retina at the back of the eye. Your macula is only about the size of the grain of rice, that’s about four millimeters across. [More]
Health Canada approves immunotherapy clinical study to treat Epstein-Barr virus-related lymphomas

Health Canada approves immunotherapy clinical study to treat Epstein-Barr virus-related lymphomas

Health Canada recently approved, for the first time in Canada, a clinical project for a Phase I study aimed at treating lymphomas associated with the Epstein-Barr virus (EBV) through adoptive cellular immunotherapy that is specific to EBV. [More]
New discovery may help researchers tackle mitochondrial diseases and age-related diseases

New discovery may help researchers tackle mitochondrial diseases and age-related diseases

Buck Institute faculty Judith Campisi, PhD, says age researchers need to stop thinking of cellular senescence, now accepted as an important driver of aging, as a single phenotype that stems from genotoxic stress. Research from her lab reveals that cellular senescence, a process whereby cells permanently lose the ability to divide, is also induced by signaling from dysfunctional mitochondria - and that the arrested cells secrete a distinctly different "stew" of biologically active factors in a process unrelated to the damaging free radicals that are created in mitochondria as part of oxygen metabolism. [More]
Ultrafast near-infrared lasers deliver gene therapy to treat macular degeneration

Ultrafast near-infrared lasers deliver gene therapy to treat macular degeneration

Millions of adults over age 50 struggle each year with vision loss caused by damage to the retina or common macular degeneration. [More]
Study identifies genetic factors that play role in AMD

Study identifies genetic factors that play role in AMD

An international study has identified the number of genetic factors known to play a role in age-related macular degeneration (AMD), the worldwide leading cause of blindness in the elderly. [More]
Study reveals new genetic factors linked to age-related macular degeneration

Study reveals new genetic factors linked to age-related macular degeneration

An international study of about 43,000 people has significantly expanded the number of genetic factors known to play a role in age-related macular degeneration (AMD), a leading cause of vision loss among people age 50 and older. [More]
Scientists identify 52 genetic variations associated with age-related macular degeneration

Scientists identify 52 genetic variations associated with age-related macular degeneration

In one of the latest examples of precision medicine, teams of geneticists from nine countries, involving more than 100 scientists, analyzed the genes of more than 33,000 individuals in the hope of finding genetic variations responsible for age-related macular degeneration (AMD), the leading cause of vision loss among people age 50 or older. [More]
New heart failure drug may increase patients' risk of Alzheimer's disease, macular degeneration

New heart failure drug may increase patients' risk of Alzheimer's disease, macular degeneration

Patients with mild heart failure stand to benefit from a new drug that can halt the progression of their disease and reduce their risk of cardiovascular-related death. But the drug -- a tablet that combines the agents valsartan and sacubitril, sold under the trade name Entresto by drugmaker Novartis -- may be too good to be true, according to Arthur M. Feldman, MD, PhD, Executive Dean of the Lewis Katz School of Medicine at Temple University, Chief Academic Officer of the Temple University Health System, and Laura H. Carnell Professor of Medicine at LKSOM. [More]
Tyrogenex announces results from phase 1 study of orally-administered X-82 in patients with AMD

Tyrogenex announces results from phase 1 study of orally-administered X-82 in patients with AMD

Tyrogenex, a privately held company focused on the development of targeted therapeutics for cancer and ophthalmology, today announced data from its phase 1 open-label study of orally-administered X-82 in patients for wet age-related macular degeneration (AMD). [More]
L-DOPA drug may delay or prevent age-related macular degeneration

L-DOPA drug may delay or prevent age-related macular degeneration

A drug already used safely to treat Parkinson's disease, restless leg syndrome and other movement disorders also could delay or prevent the most common cause of blindness affecting more than 9 million older Americans - age-related macular degeneration (AMD). [More]
Drug used to treat Parkinson's and related diseases may delay or prevent macular degeneration

Drug used to treat Parkinson's and related diseases may delay or prevent macular degeneration

In a major scientific breakthrough, a drug used to treat Parkinson's and related diseases may be able to delay or prevent macular degeneration, the most common form of blindness among older Americans. [More]
Astellas enters into definitive agreement to acquire Ocata

Astellas enters into definitive agreement to acquire Ocata

Astellas Pharma Inc. and Ocata Therapeutics, Inc., a biotechnology company focused on the research and development of new therapies in the field of regenerative medicine, primarily cell therapy addressing unmet medical needs in ophthalmology patients, announced today that they have entered into a definitive agreement. [More]
RXi Pharmaceuticals begins Phase 1/2 clinical trial in ophthalmology

RXi Pharmaceuticals begins Phase 1/2 clinical trial in ophthalmology

RXi Pharmaceuticals Corporation a biotechnology company focused on discovering and developing innovative therapies primarily in the areas of dermatology and ophthalmology today announced the initiation of a Phase 1/2 clinical trial in ophthalmology. The clinical study RXI-109-1501 will evaluate the safety and clinical activity of RXI-109 to prevent the progression of retinal scarring, a harmful component of numerous retinal diseases. [More]
Good news for patients suffering from dry age-related macular degeneration

Good news for patients suffering from dry age-related macular degeneration

Scientists have good news for patients who suffer from currently untreatable dry age-related macular degeneration (dry AMD). In a new study, researchers identified a potential target for future therapies to slow the progression of the blinding condition. Published in Investigative Ophthalmology & Visual Science, the findings indicate that treatments currently used for other conditions could also work for dry AMD. [More]
Discovery offers promising alternative to current therapies for AMD and ROP

Discovery offers promising alternative to current therapies for AMD and ROP

A research team led by scientists at Beth Israel Deaconess Medical Center and the University of New Mexico School of Medicine has identified a small molecule that treats animal models of aged macular degeneration (AMD) and retinopathy of prematurity (ROP) by preventing the overgrowth of blood vessels that are characteristic of these two retinal diseases. [More]
Charles Bonnet syndrome: an interview with Dr. Dominic ffytche

Charles Bonnet syndrome: an interview with Dr. Dominic ffytche

Charles Bonnet syndrome is the name we give to the visual hallucinations associated with eye disease. There are lots of different causes of visual hallucinations. Many different medical problems and medications can cause them, but, when the cause is eye disease, it's referred to as Charles Bonnet Syndrome after Charles Bonnet, who was a natural philosopher in the 18th century. [More]
Franziska Michor named recipient of NYSCF - Robertson Stem Cell Prize

Franziska Michor named recipient of NYSCF - Robertson Stem Cell Prize

The New York Stem Cell Foundation announced today that Franziska Michor, PhD, is the 2015 recipient of the NYSCF - Robertson Stem Cell Prize for her work pioneering new approaches to study the growth, spread, and treatment of cancer. Her laboratory fuses her passions in mathematics, molecular biology and patient care to investigate how cancers form and progress. [More]
NYSCF conference to focus on translational stem cell and neuroscience research

NYSCF conference to focus on translational stem cell and neuroscience research

The New York Stem Cell Foundation 10th Annual Translational Stem Cell Research Conference convenes global leaders in translational stem cell and neuroscience research to present their latest work towards new treatments and cures for the most devastating diseases and injuries currently facing the world. [More]
NAM announces election of three new members from UC San Diego School of Medicine

NAM announces election of three new members from UC San Diego School of Medicine

The National Academy of Medicine announced today the election of three new members from University of California, San Diego School of Medicine: Napoleone Ferrara, MD; Christopher K. Glass, MD, PhD; and Roberto Malinow, MD, PhD. Election to NAM is considered among the highest honors in the fields of health and medicine. [More]
Advertisement
Advertisement